ETNB - NASDAQ
89bio, Inc.
$14.84
+0.0000%89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
At a Glance
Live Snapshotetnb
Stock Based Compensation
Last Annual Value
20.63M
3-Year CAGR
33%
5-Year CAGR
121%
10-Year CAGR
69%
89bio, Inc. Competitors Analysis of Stock Based Compensation
| Company | Stock Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
89bio, Inc. NASDAQ:ETNB | 20.63M | 8.6% | 18.9% | N/A | |
 Agios Pharmaceuticals, Inc. NASDAQ:AGIO | 52.55M | 5.5% | -0.4% | 2.2% | |
 Beam Therapeutics Inc. NASDAQ:BEAM | 94.24M | -1.5% | 16.7% | N/A | |
 Cogent Biosciences, Inc. NASDAQ:COGT | 46.08M | 14.6% | 31.6% | 46.4% | |
 Denali Therapeutics Inc. NASDAQ:DNLI | 99.63M | -2.7% | 3.2% | 42.2% | |
 ImmunityBio, Inc. NASDAQ:IBRX | 0.00 | N/A | N/A | N/A | |
 Liquidia Corporation NASDAQ:LQDA | 29.47M | 43.0% | 34.3% | 55.9% | |
 Ocular Therapeutix, Inc. NASDAQ:OCUL | 43.18M | 34.3% | 23.6% | 21.9% | |
 Arcus Biosciences, Inc. NYSE:RCUS | 60.00M | -6.3% | 1.8% | 91.6% | |
 Recursion Pharmaceuticals, Inc. NASDAQ:RXRX | 111.22M | 27.6% | 49.6% | N/A |
89bio, Inc. Fair Value Envelope
Related Guides
Continue your ETNB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.